arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Xencor Inc

XNCR
$34.03 ▼ -1.00 (-2.85%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
56 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

Xencor Inc faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $2.6B
Dividend Yield —
Revenue Growth 17.5% ↗
Op. Margin -72.4%
ROIC -6.3% ↗
FCF / Share $-0.74 ↗
Trailing P/E —
Price / Book 5.0x
FCF Yield —
Debt / Equity 0.15
info Valuation on last close. End-of-day price, Nov 5, 2026.

56-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$51.22M
↑ +17.5% —
Net Income Profit after all expenses
$-21.73M
↑ +29.5% —
Operating Margin Operating profit as % of sales
-72.4%
↑ +61.9% 1th
FCF / Share Free cash flow per share
$-0.74
↑ +18.3% —
Long-Term Debt Long-term obligations
$77.54M
↓ -5.6% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
2
Returns
31
Financial Health
40
Cash Quality
80

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 15 years · 56 quarters